Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
1. A compound of formula I
wherein
X denotes N,
R 1 denotes NH 2 , or CONH 2 ,
R 2 denotes Hal, Ar 1 or Het 1 ,
R 3 denotes NR 5 [C(R 5 ) 2 ] n Het 2 , Het 2 , O[C(R 5 ) 2 ] n Het 2 , NR 5 (CH 2 ) p NR 5 R 6 , O(CH 2 ) p NR 5 R 6 or NR 5 (CH 2 ) p CR 7 R 8 NR 5 R 6 ,
R 4 denotes H, CH 3 or NH 2 ,
R 5 is each independently H or alkyl having 1, 2, 3 or 4 C atoms,
R 6 is each independently N(R 5 ) 2 CH 2 CH═CHCONH, Het 3 CH 2 CH═CHCONH, CH 2 ═CHCONH(CH 2 ) n , Het 4 (CH 2 ) n COHet 3 -diyl-CH 2 CH═CHCONH, HC≡CCO, CH 3 C≡CCO, CH 2 ═CH—CO, CH 2 ═C(CH 3 )CONH, CH 3 CH═CHCONH(CH 2 ) n , N≡CCR 7 R 8 CONH(CH 2 ) n , Het 4 NH(CH 2 ) p COHet 3 -diyl -CH 2 CH═CHCONH, Het 4 (CH 2 ) p CONH(CH 2 CH 2 O) p (CH 2 ) p COHet 3 -diyl-CH 2 CH═CHCONH, CH 2 ═CHSO 2 , ACH═CHCO, CH 3 CH═CHCO, Het 4 (CH 2 ) p CONH(CH 2 ) p Het 3 -diyl-CH 2 CH═CHCONH, Ar 3 CH═CHSO 2 , CH 2 ═CHSO 2 NH or N(R 5 )CH 2 CH═CHCO,
R 7 , R 8 denote together alkylene having 2, 3, 4, or 5 C atoms,
Ar 1 denotes phenyl or naphthyl, each of which is unsubstituted or mono-, di- or trisubstituted by R 6 , Hal, (CH 2 ) n NH 2 , CONHAr 3 , (CH 2 ) n NHCOA, O(CH 2 ) n Ar 3 , OCyc, A, COHet 3 , OA and/or OHet 3 (CH 2 ),
Ar 3 is each independently phenyl, which is unsubstituted or mono-, di- or trisubstituted by OH, OA, Hal, CN and/or A,
Het 1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by R 6 , O(CH 2 ) n Ar 3 and/or (CH 2 ) n Ar 3 ,
Het 2 is each independently a mono- or bicyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by R 6 , Het 3 , CycSO 2 , OH, Hal, COOH, OA, COA, COHet 3 , CycCO, SO 2 and/or ═O,
Het 3 is each independently a monocyclic unsaturated, saturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or ═O,
Het 4 is each independently a bi- or tricyclic unsaturated, saturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di-, tri- or tetrasubstituted by A, NO 2 , Hal and/or ═O,
Cyc is each independently cyclic alkyl having 3, 4, 5 or 6 C atoms, which is unsubstituted, monosubstituted or disubstituted by R 6 and/or OH and which may comprise a double bond,
A is each independently unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or Cl and/or in which one or two non-adjacent CH 2 and/or CH-groups may be replaced by O, NH and/or by N,
Hal is each independently F, Cl, Br or I,
n is each independently 0, 1, 2, 3 or 4,
p is each independently 1, 2, 3, 4, 5 or 6,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
2. A compound according to claim 1 wherein
Het 1 denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, indazolyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, imidazolidinyl, azetidinyl, azepanyl, benzo-2,1,3-thiadiazolyl, tetrahydrofuryl, dioxolanyl, tetrahydrothienyl, dihydropyrrolyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydropyridyl, dihydropyridyl or dihydrobenzodioxinyl, each of which is unsubstituted or mono-, di- or trisubstituted by R 6 , O(CH 2 ) n Ar 3 and/or (CH 2 ) n Ar 3 , and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
3. A compound according to claim 2 wherein
Het 1 denotes pyrazolyl, pyridyl, pyrimidinyl, dihydropyridyl or dihydrobenzodioxinyl, each of which is unsubstituted or mono-, di- or trisubstituted by R 6 , O(CH 2 ) n Ar 3 and/or (CH 2 ) n Ar 3 , and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
4. A compound according to claim 1 wherein
Het 2 denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[4.4]nonyl, 3-azabicylo[3.1.0]hexyl, 2-azaspiro[3.3]heptyl, 6-azaspiro[3.4]octyl, 7-azaspiro[3.5]nonyl, 5-azaspiro[3.5]nonyl, imidazolidinyl, azetidinyl, azepanyl, tetrahydrofuryl, dioxolanyl, tetrahydrothienyl, tetrahydroimidazolyl, tetrahydropyrazolyl, tetrahydropyridyl, each of which is unsubstituted or mono-, di- or trisubstituted by R 6 , Het 3 , CycSO 2 , OH, OA, COA, COHet 3 , CycCO, SO 2 and/or ═O, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
5. A compound according to claim 1 wherein
Het 3 denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, imidazolidinyl, azetidinyl, azepanyl, tetrahydrofuryl, dioxolanyl, tetrahydrothienyl, dihydropyrrolyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydropyridyl or dihydropyridyl, each of which may be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or ═O,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
6. A compound according to claim 5 wherein
Het 3 denotes piperidinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, dihydropyrrolyl, dihydropyrazolyl or dihydropyridyl, each of which may be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or ═O,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
7. A compound according to claim 1 wherein
Het 4 denotes hexahydrothieno[3,4-d]imidazolyl, benzo[c][1,2,5]oxadiazolyl or 5H-dipyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinin-4-ium-uidyl, each of which may be unsubstituted or mono-, di-, tri- or tetrasubstituted by A, NO 2 , Hal and/or ═O, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
8. A compound according to claim 1 wherein
X denotes N,
R 1 denotes NH 2 , or CONH 2 ,
R 2 denotes Hal, Ar 1 or Het 1 ,
R 3 denotes NR 5 [C(R 5 ) 2 ] 9 Het 2 , Het 2 , O[C(R 5 ) 2 ] n Het 2 , NR 5 (CH 2 ) p NR 5 R 6 , O(CH 2 ) p NR 5 R 6 NR 5 (CH 2 ) p CR 7 R 8 NR 5 R 6 ,
R 4 denotes H,
R 5 is each independently H or alkyl having 1, 2, 3 or 4 C atoms,
R 6 is each independently N(R 5 ) 2 CH 2 CH═CHCONH, Het 3 CH 2 CH═CHCONH, CH 2 ═CHCONH(CH 2 ) n , Het 4 (CH 2 ) n COHet 3 -diyl-CH 2 CH═CHCONH, HC≡CCO, CH 3 C≡CCO, CH 2 ═CH—CO, CH 2 ═C(CH 3 )CONH, CH 3 CH═CHCONH(CH 2 ) n , N≡CCR 7 R 8 CONH(CH 2 ) n , Het 4 NH(CH 2 ) p COHet 3 -diyl-CH 2 CH═CHCONH, Het 4 (CH 2 ) p CONH(CH 2 CH 2 O) p (CH 2 ) p COHet 3 -diyl-CH 2 CH═CHCONH, CH 2 ═CHSO 2 , ACH═CHCO, CH 3 CH═CHCO, Het 4 (CH 2 ) p CONH(CH 2 ) p Het 3 -diyl-CH 2 CH═CHCONH, Ar 3 CH═CHSO 2 , CH 2 ═CHSO 2 NH or N(R 5 )CH 2 CH═CHCO,
R 7 , R 8 denote together alkylene having 2, 3, 4, or 5 C atoms,
Ar 1 denotes phenyl or naphthyl, each of which is unsubstituted or mono-, di- or trisubstituted by R 6 , Hal, (CH 2 ) n NH 2 , CONHAr 3 , (CH 2 ) n NHCOA, O(CH 2 ) n Ar 3 , OCyc, A, COHet 3 , OA and/or OHet 3 (CH 2 ),
Ar 3 is each independently phenyl, which is unsubstituted or mono-, di- or trisubstituted by OH, OA, Hal, CN and/or A,
Het 1 denotes piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, indazolyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, imidazolidinyl, azetidinyl, azepanyl, benzo-2,1,3-thiadiazolyl, tetrahydrofuryl, dioxolanyl, tetrahydrothienyl, dihydropyrrolyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydropyridyl, dihydropyridyl or dihydrobenzodioxinyl, each of which is unsubstituted or mono-, di- or trisubstituted by R 6 , O(CH 2 ) n Ar 3 and/or (CH 2 ) n Ar 3 ,
Het 2 is each independently piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[4.4]nonyl, 3-azabicylo[3.1.0]hexyl, 2-azaspiro[3.3]heptyl, 6-azaspiro[3.4]octyl, 7-azaspiro[3.5]nonyl, 5-azaspiro[3.5]nonyl, imidazolidinyl, azetidinyl, azepanyl, tetrahydrofuryl, dioxolanyl, tetrahydrothienyl, tetrahydroimidazolyl, tetrahydropyrazolyl, tetrahydropyridyl, each of which is unsubstituted or mono-, di- or trisubstituted by R 6 , Het 3 , CycSO 2 , OH, OA, COA, COHet 3 , CycCO, SO 2 and/or ═O,
Het 3 is each independently piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, imidazolidinyl, azetidinyl, azepanyl, tetrahydrofuryl, dioxolanyl, tetrahydrothienyl, dihydropyrrolyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydropyridyl or dihydropyridyl, each of which may be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or ═O,
Het 4 is each independently hexahydrothieno[3,4-d]imidazolyl, benzo[c][1,2,5]oxadiazolyl or 5H-dipyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinin-4-ium-uidyl, each of which may be unsubstituted or mono-, di-, tri- or tetrasubstituted by A, NO 2 , Hal and/or ═O,
Cyc is each independently cyclic alkyl having 3, 4, 5 or 6 C atoms, which is unsubstituted or monosubstituted by R 6 and which may comprise a double bond,
A is each independently unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or Cl and/or in which one or two non-adjacent CH 2 and/or CH-groups may be replaced by O, NH and/or by N,
Hal is each independently F, Cl, Br or I,
n is each independently 0, 1, 2, 3 or 4,
p is each independently 1, 2, 3, 4, 5 or 6,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.